TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management
Authors:
Open Access
- 21 November 2018
- journal article
- review article
- Published by SAGE Publications in Journal of Psoriasis and Psoriatic Arthritis®
- Vol. 4 (2) , 70-80
Abstract
Tumor necrosis factor α (TNF-α)-targeted therapies have expanded the therapeutic options for patients with inflammatory bowel disease (IBD), rheumatoid arthritis (RA), psoriasis, and psoriatic arthritis (PsA) and have significantly improved patients’ quality of life. Paradoxically, anti-TNF-α agents may induce psoriatic eruptions or worsen preexisting psoriatic skin disease. Currently, there is no standard approach for the management of TNF inhibitor-induced psoriasis. Here, we conduct a literature review on TNF inhibitor-induced psoriasis and introduce a novel treatment algorithm for maintaining otherwise effective anti-TNF therapy versus switching to a different class as appropriate in the management of patients with IBD, RA, psoriasis, or PsA.Keywords
This publication has 106 references indexed in Scilit:
- Rituximab or a second anti–tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti–tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics RegisterArthritis Care & Research, 2012
- Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatmentAnnals of the Rheumatic Diseases, 2012
- Hypersensitivity Reactions to Dapsone: A Systematic ReviewActa Dermato-Venereologica, 2012
- The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A systematic review and meta-analysis of randomized controlled trialsJournal of the American Academy of Dermatology, 2011
- New onset psoriasis in a patient receiving abatacept for rheumatoid arthritisBMJ Case Reports, 2009
- Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: results from the British Society for Rheumatology Biologics RegisterAnnals of the Rheumatic Diseases, 2009
- Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trialAnnals of the Rheumatic Diseases, 2007
- Tumour necrosis factor inhibition causing psoriasis? A more plausible explanation existsAnnals of the Rheumatic Diseases, 2006
- IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2–dependent mechanisms with implications for psoriasis pathogenesisJournal of Experimental Medicine, 2006
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006